MX2021004280A - Derivados de pirazol como compuestos antagonistas de receptor de histamina h4. - Google Patents

Derivados de pirazol como compuestos antagonistas de receptor de histamina h4.

Info

Publication number
MX2021004280A
MX2021004280A MX2021004280A MX2021004280A MX2021004280A MX 2021004280 A MX2021004280 A MX 2021004280A MX 2021004280 A MX2021004280 A MX 2021004280A MX 2021004280 A MX2021004280 A MX 2021004280A MX 2021004280 A MX2021004280 A MX 2021004280A
Authority
MX
Mexico
Prior art keywords
pyrazole derivatives
antagonist compounds
sup
compounds
ameliorating
Prior art date
Application number
MX2021004280A
Other languages
English (en)
Spanish (es)
Inventor
Giles Albert Brown
Miles Stuart Congreve
Mark Pickworth
Charlotte Fieldhouse
Barry John Teobald
Nigel Alan Swain
Giovanni Bottegoni
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of MX2021004280A publication Critical patent/MX2021004280A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2021004280A 2018-10-19 2019-10-21 Derivados de pirazol como compuestos antagonistas de receptor de histamina h4. MX2021004280A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1817047.2A GB201817047D0 (en) 2018-10-19 2018-10-19 H4 antagonist compounds
PCT/GB2019/052997 WO2020079457A1 (en) 2018-10-19 2019-10-21 Pyrazole derivatives as h4 antagonist compounds

Publications (1)

Publication Number Publication Date
MX2021004280A true MX2021004280A (es) 2021-05-31

Family

ID=64453795

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004280A MX2021004280A (es) 2018-10-19 2019-10-21 Derivados de pirazol como compuestos antagonistas de receptor de histamina h4.

Country Status (13)

Country Link
US (2) US12234227B2 (https=)
EP (1) EP3867248B1 (https=)
JP (1) JP7532353B2 (https=)
KR (1) KR102873380B1 (https=)
CN (1) CN113272297B (https=)
AU (1) AU2019360428B2 (https=)
BR (1) BR112021007372A2 (https=)
CA (1) CA3116628A1 (https=)
ES (1) ES3058587T3 (https=)
GB (1) GB201817047D0 (https=)
MX (1) MX2021004280A (https=)
SG (1) SG11202103133QA (https=)
WO (1) WO2020079457A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005858D0 (en) * 2020-04-22 2020-06-03 Heptares Therapeutics Ltd H4 Antagonist compounds
GB202019667D0 (en) * 2020-12-14 2021-01-27 Heptares Therapeutics Ltd H4 antagonist comnpounds
WO2022203399A1 (ko) * 2021-03-26 2022-09-29 주식회사 스탠다임 아데노신 a2a 수용체 길항제 및 이의 용도
WO2022232259A1 (en) * 2021-04-28 2022-11-03 Cornell University Soluble adenylyl cyclase (sac) inhibitors and uses thereof
EP4421067A4 (en) * 2021-10-19 2026-01-14 Unimatec Co Ltd PYRAZOLE COMPOUND CONTAINING FLUORIDE AND ITS PRODUCTION PROCESS
KR102621694B1 (ko) * 2022-09-15 2024-01-08 주식회사 스탠다임 아데노신 a2a 수용체 길항제 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000169475A (ja) 1998-07-24 2000-06-20 Dai Ichi Seiyaku Co Ltd ピラゾ―ル誘導体およびその塩
US6573377B1 (en) * 1998-07-24 2003-06-03 Daiichi Pharmaceuticals Co., Ltd. Pyrazole derivatives and salts thereof
WO2005054239A1 (en) 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20100035863A1 (en) 2006-09-12 2010-02-11 Ucb Pharma, S.A. 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
US7985745B2 (en) * 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
CL2008000467A1 (es) 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
WO2009068512A1 (en) 2007-11-30 2009-06-04 Palau Pharma, S. A. 2 -amino-pyrimidine derivatives as histamine h4 antagonists
PE20091524A1 (es) 2007-12-19 2009-09-25 Palau Pharma Sa Derivados de 2-aminopirimidina
CN101903385B (zh) 2007-12-21 2013-11-06 帕劳制药股份有限公司 作为组胺h4受体拮抗剂的4-氨基嘧啶衍生物
AR074199A1 (es) * 2008-11-20 2010-12-29 Glaxosmithkline Llc Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer.
TW201035078A (en) 2009-03-20 2010-10-01 Incyte Corp Substituted heterocyclic compounds
MX2012004995A (es) 2009-10-29 2012-10-03 Sirtris Pharmaceuticals Inc Piridinas biciclicas y analogos como moduladores de sirtuina.
WO2011076878A1 (en) 2009-12-23 2011-06-30 Palau Pharma, S.A. Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists
US9580443B2 (en) 2012-11-16 2017-02-28 Merck Patent Gmbh Heterocyclic derivatives as modulators of kinase activity
US11401255B2 (en) 2016-07-28 2022-08-02 Mayo Foundation For Medical Education And Research Small molecule activators of Parkin enzyme function

Also Published As

Publication number Publication date
EP3867248B1 (en) 2025-12-10
KR102873380B1 (ko) 2025-10-23
CA3116628A1 (en) 2020-04-23
EP3867248A1 (en) 2021-08-25
CN113272297B (zh) 2024-03-19
US20250115587A1 (en) 2025-04-10
WO2020079457A1 (en) 2020-04-23
US20210300906A1 (en) 2021-09-30
GB201817047D0 (en) 2018-12-05
US12234227B2 (en) 2025-02-25
SG11202103133QA (en) 2021-05-28
CN113272297A (zh) 2021-08-17
ES3058587T3 (en) 2026-03-11
KR20210079318A (ko) 2021-06-29
JP7532353B2 (ja) 2024-08-13
AU2019360428B2 (en) 2024-05-09
EP3867248C0 (en) 2025-12-10
JP2022507013A (ja) 2022-01-18
BR112021007372A2 (pt) 2021-07-20
AU2019360428A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
MX2021004280A (es) Derivados de pirazol como compuestos antagonistas de receptor de histamina h4.
MX2022005111A (es) Compuestos moduladores del receptor 52 acoplado a proteina g (gpr52).
MX371167B (es) Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
ZA202206923B (en) New methylquinazolinone derivatives
GEAP202415986A (en) Substituted aminoquinolones as dgkalpha inhibitors for immune activation
NZ736665A (en) Heterocyclic amides as kinase inhibitors
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EP4252848A3 (en) Oxysterols and methods of use thereof
MX390302B (es) Oxiesteroles y metodos de uso de los mismos
MX372624B (es) Compuestos de benzoxacepina oxazolidinona y metodos de uso
MX375718B (es) [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos.
MX2020012978A (es) Sales de sepiapterina farmacéuticamente aceptables.
MY207696A (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
MY206763A (en) Piperidinyl-3-(aryloxy)propanamides and propanoates
MX2020002824A (es) Aminas beta-hidroxi heterociclicas y su uso en el tratamiento de la hiperglucemia.
PH12021551157A1 (en) Ketamine pamoate and use thereof
SG10201806809QA (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
PH12022551531A1 (en) Substituted thiophene carboxamides and derivatives thereof as microbicides
PH12019501566B1 (en) Amide compounds and use thereof
MX2020010086A (es) Métodos y composiciones para tratar alucinaciones y afecciones relacionadas con las mismas.
MX2022005024A (es) Profarmacos de fosforo de estimuladores de guanilato ciclasa soluble (sgc).
CL2024000742A1 (es) Compuestos moduladores de gpr52
ZA202110676B (en) Substituted thiophene carboxamides and derivatives thereof as microbicides
WO2020074927A3 (en) Glp-1 receptor antagonists
EP4595969A8 (en) Compositions and methods for treatment of insulin resistance